Active substance: ceftriaxone (Injectable 3rd generation cephalosporin)
Form: 500 mg Powder and solvent for solution for injection (IV injection -perfusion)
1000 mg Powder and solvent for solution for injection (IV injection – perfusion – IM injection)
Dosage: 500 mg / 1000 mg of ceftriaxone per vial
Target: adults and children (including in term neonates)
Cetafor is indicated for the treatment of the following infections in adults and children
including term neonates (from birth):
Cetafor may be used:
Cetafor should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.
The dose depends on the severity, susceptibility, site and type of infection and on the
age and hepato-renal function of the patient.
The duration of therapy varies according to the course of the disease. As with antibiotic
therapy in general, administration of ceftriaxone should be continued for 48 – 72 hours
after the patient has become afebrile or evidence of bacterial eradication has been
IV bolus injection :
Cetafor® IV (500mg and 1000mg) should be administered by intravenous injection. The solution is prepared with the 5ml/10ml ampoule supplied in the same box. The solution should be administered directly after reconstitution by the IV route over a period of 2 to 4 minutes.
Concentrations between 10 mg/ml and 40 mg/ml are recommended.
Cetafor 1000 IV and 500 mg IV should be dissolved in one of the following solutions: 0.9% sodium chloride – 5% glucose or 10% – 5% glucose + 0.9% sodium chloride – 5% glucose + 0.45% sodium chloride.
All these solutions must be administered immediately after reconstitution.Les solutions contenant de la ceftriaxone ne doivent pas être mélangées ou ajoutées à d’autres agents. En particulier, ceftriaxone n’est pas compatible avec des solutions contenant du calcium. La ceftriaxone ne doit pas être mélangée ou administrée simultanément avec des solutions contenant du calcium.
Prescription drugs. Please contact your doctor.
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.